Unknown NA INTERVENTIONAL 1-arm NCT05383547

Bortezomib for Treating Glomerular Diseases

Prospective Observation of Bortezomib in the Treatment of Glomerular Diseases

Sponsor: Ruijin Hospital

Conditions Bortezomib FSGS Glomerulonephritis IgA Nephropathy MN MPGN

Interventions Bortezomib

Updated 5 times since 2022 Last updated: Oct 28, 2022 Started: Aug 2, 2022 Primary completion: Dec 31, 2023 Completion: Dec 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05383547, this NA trial focuses on Bortezomib and FSGS and remains ongoing. Sponsored by Ruijin Hospital, it has been updated 5 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jun 2024 — Jul 2024 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Nov 2022 — Jun 2024 [monthly]

Recruiting NA
Jun 2022 — Nov 2022 [monthly]

Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ruijin Hospital

Data source: Ruijin Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China